Secondary outcome measures include changes in DASH-E at @ and @ months , changes in pain as assessed by the visual analogue scale ( VAS ) at the @-week , @ - , @ - , and @-month follow-up , changes in sonographic features and neovascularity , and percentage of patients in each group with adverse reactions at @ , @ , and @ months .